DR. JAMES B DALE, MD
Osteopathic Medicine at Nonconnah Blvd, Memphis, TN
License number
Tennessee 14124
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
1910 Nonconnah Blvd SUITE 120, Memphis, TN 38132
Phone
(901) 448-2300
(901) 448-6657 (Fax)
(901) 448-7642
(901) 448-8015 (Fax)
(901) 448-6657 (Fax)
(901) 448-7642
(901) 448-8015 (Fax)
Personal information
See more information about JAMES B DALE at radaris.comName
Address
Phone
506 Menees Ln, Madison, TN 37115
6029 Sherwood Dr, Nashville, TN 37215
5562 Pine Oak Ln, Memphis, TN 38135
3884 Saint Andrews Grn, Memphis, TN 38111
474 Turkeytown Rd, Hilham, TN 38568
Organization information
See more information about JAMES B DALE at bizstanding.comJames B Dale MD
956 Ct Ave STE E332, Memphis, TN 38103
Categories:
Physicians & Surgeons
Phone:
(901) 448-5914 (Phone)
Professional information
James B Dale, Memphis TN
Specialties:
Internal Medicine, Infectious Disease
Work:
Utmg Infectious Disease
1030 Jefferson Ave, Memphis, TN 38104 UT Medical Group
880 Madison Ave, Memphis, TN 38103
1030 Jefferson Ave, Memphis, TN 38104 UT Medical Group
880 Madison Ave, Memphis, TN 38103
Education:
University of Tennessee (1977)
James B Dale, Memphis TN
Specialties:
Infectious Disease Specialist
Address:
1910 Nonconnah Blvd, Memphis, TN 38132
Group A Streptococcal Vaccines
US Patent:
6716433, Apr 6, 2004
Filed:
Sep 10, 1998
Appl. No.:
09/151409
Inventors:
James B. Dale - Memphis TN
Assignee:
University of Tennessee Research Foundation - Knoxville TN
International Classification:
A61K 3909
US Classification:
4242441, 4241921, 4242341, 4241841, 530300, 530328, 530350, 530825, 514 2, 435 697, 435 693
Abstract:
The present invention provides immunogenic synthetic fusion polypeptide which stimulates an immune response against a selected pathogen, comprising at least two immunogenic polypeptides from a Group A streptococci of at least 10 amino acids in length which are capable of stimulating an immune response against Group A strepococci, and a peptide C terminal to the immunogenic polypeptide which protects the immunogenicity of the immunogenic portion, wherein the C-terminal peptide is not required to stimulate an immune response against Group A streptococci.
Protective Antigen Of Group A
US Patent:
7063850, Jun 20, 2006
Filed:
Dec 22, 1999
Appl. No.:
09/471817
Inventors:
James B. Dale - Memphis TN, US
Assignee:
University of Tennessee Research Foundation - Knoxville TN
International Classification:
A61K 39/02, A61K 39/09, A61K 39/38, A61K 38/00, C07K 1/00
US Classification:
4241901, 4242341, 4242441, 4241841, 530350, 530825, 530300, 514 2
Abstract:
The present invention provides the discovery of a new protective antigen (herein designated Spa) which has been identified and isolated from Streptococci. Spa is a surface antigen distinct from M protein which evokes opsonic antibodies that are protective against multiple serotypes of streptococci. The invention further provides isolated Spa polypeptides, proteins, peptides, and antibodies against the same, as well as nucleic acids encoding Spa polypeptide and peptide antigens. Also provided are methods for identification and isolation of a Spa polypeptide, therapeutic compositions comprised of Spa antigens or antibodies and methods of their use in protecting an animal against a infection.
Recombinant Multivalent M Protein Vaccine
US Patent:
6063386, May 16, 2000
Filed:
Sep 15, 1997
Appl. No.:
8/937271
Inventors:
James B. Dale - Memphis TN
James W. Lederer - Advance NC
James W. Lederer - Advance NC
Assignee:
University of Tennessee Research Corporation - Knoxville TN
International Classification:
A61K 3909
US Classification:
4242441
Abstract:
A recombinant multivalent hybrid protein vaccine against multiple serotypes of group A streptococci that may result in rheumatic fever. The vaccine can also evoke other protective antibodies of the mucosal type DNA sequences e. g. genes which encode the necessary amino acids that carry our the desired epitopes. A method of vaccination against streptococcal infections and compositions for carrying out the same.
Group A Streptococcal Vaccines
US Patent:
7402316, Jul 22, 2008
Filed:
Feb 17, 2004
Appl. No.:
10/780106
Inventors:
James B Dale - Memphis TN, US
Assignee:
University of Tennessee Research Foundation - Knoxville TN
International Classification:
A61K 39/09, A61K 39/02, A61K 39/00, A61K 39/04
US Classification:
4242441, 4241921, 4242341, 4241841, 530300, 530328, 530350, 530825, 514 2
Abstract:
The present invention provides methods for eliciting an immune response against Group A , comprising use of recombinant fusion polypeptides, and compositions thereof, that include a multivalent immunogenic portion of at least two immunogenic polypeptides from Group A M proteins (which are capable of stimulating a protective immune response against Group A ), and a reiterated polypeptide from the immunogenic portion carboxy-terminal to the immunogenic portion, wherein the carboxy-terminal polypeptide is not required to stimulate an immune response against Group A.
Streptococcal Streptolysin S Vaccines
US Patent:
2007009, May 3, 2007
Filed:
Aug 11, 2006
Appl. No.:
11/503575
Inventors:
James Dale - Memphis TN, US
Assignee:
University of Tennessee Research Corporation - Knoxville TN
International Classification:
A61K 39/02, C07K 14/315
US Classification:
424190100, 530350000
Abstract:
Provided are streptolysin S (SLS) polypeptides, peptides, and variants thereof, antibodies directed thereto, and isolated nucleic acids encoding such proteins. In one embodiment, a method is provided wherein a synthetic peptide of SLS is used to elicit an immune response specific for SLS in a subject to treat or prevent a streptococcal infection. In other embodiments, antibodies that neutralize the hemolytic activity of the SLS toxin may be used as a vaccinating agent.
Group A Streptococcal Vaccines
US Patent:
2009003, Feb 5, 2009
Filed:
Jun 27, 2008
Appl. No.:
12/163721
Inventors:
James B. Dale - Memphis TN, US
Assignee:
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION - Knoxville TN
International Classification:
A61K 39/09, C07K 14/315, A61K 38/21, A61K 38/20, A61P 31/04
US Classification:
424 852, 530403, 4241921, 424 855
Abstract:
The present invention provides methods for eliciting an immune response against Group A streptococci, comprising use of recombinant fusion polypeptides, and compositions thereof, that include a multivalent immunogenic portion of at least two immunogenic polypeptides from Group A streptococci M proteins (which are capable of stimulating a protective immune response against Group A streptococci), and a reiterated polypeptide from the immunogenic portion carboxy-terminal to the immunogenic portion, wherein the carboxy-terminal polypeptide is not required to stimulate an immune response against Group A streptococci.
Multivalent Streptococcal Vaccine Compositions And Methods For Use
US Patent:
7270827, Sep 18, 2007
Filed:
Oct 28, 2002
Appl. No.:
10/284400
Inventors:
Mark A. Reddish - Woodinville WA, US
Mary ChaoHong Hu - Edmonds WA, US
Michael A. Walls - Kenmore WA, US
James B. Dale - Memphis TN, US
Mary ChaoHong Hu - Edmonds WA, US
Michael A. Walls - Kenmore WA, US
James B. Dale - Memphis TN, US
Assignee:
University of Tennessee Research Foundation - Knoxville TN
ID Biomedical Corporation of Washington - Bothell WA
ID Biomedical Corporation of Washington - Bothell WA
International Classification:
A61K 39/09, A61K 39/02, A61K 39/116, A61K 39/00, A61K 38/00, C07K 1/00, C07K 2/00
US Classification:
4242441, 4242341, 4241921, 4242031, 4241901, 4241841, 514 2, 530350, 530300, 530825, 530806
Abstract:
Compositions and methods for making and using therapeutic formulations of multivalent hybrid polypeptides comprising immunogenic peptides of M proteins from various different serotypes of group A streptococci and antibodies thereto are provided. Also provided are nucleic acids encoding such hybrid polypeptides. The hybrid polypeptide formulations may be used, for example, in methods for treating or preventing a microbial infection and eliciting a protective immune response having broadly protective opsonic antibodies in the absence of tissue cross-reactive antibodies.
Antigen Of Hybrid M Protein And Carrier For Group A Streptococcal Vaccine
US Patent:
2007005, Mar 8, 2007
Filed:
May 1, 2006
Appl. No.:
11/415382
Inventors:
James Dale - Memphis TN, US
Assignee:
University of Tennessee Research Foundation - Knoxville TN
International Classification:
A61K 39/09, C07K 14/315
US Classification:
424244100, 530350000
Abstract:
Recombinant hybrid streptococcal M protein antigens are provided which elicit protective antibodies against Group A streptococci and prevent rheumatic fever. Recombinant hybrid genes that encode the antigen are provided. Vaccine compositions and methods of administering the compositions are provided to elicit immunity against Group A streptococci.